Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Gregory Seymour

Hematology & Oncology Kingwood, TX Medical Doctor

NPI 1720041056 CMS profile 259969

22710 Professional Dr, Kingwood, TX 77339

Open in the dashboard

General payments

$8,928

502 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Gregory Seymour of Kingwood, TX is reported in the CMS Open Payments database as having received $8,928 across 502 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $64 3
2022 General $2,724 126
2021 General $2,603 153
2020 General $1,416 85
2019 General $2,122 135

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Seymour
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Gregory Seymour were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Gregory Seymour Hematology & Oncology median Middle half National median
2019 $2,122 $529 $121–$2,516 $163
2020 $1,416 $339 $82–$2,213 $114
2021 $2,603 $263 $49–$1,965 $132
2022 $2,724 $416 $103–$2,395 $149
2023 $64 $542 $125–$2,646 $160
2024 $0 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Biotech, Inc. $781 42 payments
  2. Pfizer Inc. $697 45 payments
  3. Novartis Pharmaceuticals Corporation $659 40 payments
  4. Astellas Pharma US Inc $547 17 payments
  5. Merck Sharp & Dohme Corporation $513 30 payments
  6. E.R. Squibb & Sons, L.L.C. $484 36 payments
  7. Seattle Genetics, Inc. $365 23 payments
  8. GlaxoSmithKline, LLC. $345 16 payments
  9. Lilly USA, LLC $341 21 payments
  10. Celgene Corporation $263 14 payments
  11. Other $3,934 218 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $8,513 494 payments
  2. Education $415 8 payments
Products named General payments · program years 2019–2023
  1. DARZALEX $549 30 payments
  2. IMBRUVICA $515 30 payments
  3. KEYTRUDA $415 25 payments
  4. IBRANCE $354 19 payments
  5. OPDIVO $296 23 payments
  6. XTANDI $285 20 payments
  7. VERZENIO $274 17 payments
  8. CYRAMZA $212 14 payments
  9. ZEJULA $207 10 payments
  10. BLENREP $200 9 payments
  11. Other $7,373 434 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

502 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record